Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2024-11-20 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
深圳微芯生物科技股份有限公司关于本次募集资金投向属于科技创新领域的说明
Capital/Financing Update Classification · 95% confidence The document is a detailed explanation regarding the use of funds raised through a specific stock issuance by Shenzhen Microcore Biotech Co., Ltd. It discusses the company's business, the purpose of the fundraising, the allocation of funds towards innovative drug R&D and working capital, and compliance with relevant laws and policies. The document references the company's strategic plans, R&D projects, and regulatory environment but does not contain financial statements or quarterly/yearly financial results. It is a disclosure about capital raising and the intended use of proceeds, consistent with a Capital/Financing Update filing rather than an annual or interim report or earnings release. The length and detail confirm it is not a brief announcement but a substantive update on financing activities.
2024-11-20 Chinese
前次募集资金使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use of previously raised funds by Shenzhen Microchip Biotechnology Co., Ltd. It includes specifics on the amounts raised in prior capital raising events (2019 IPO and 2022 convertible bonds), the storage and usage of these funds, changes in investment projects, investment benefits, and cash management of idle funds. It references regulatory requirements from the China Securities Regulatory Commission and includes audited verification reports from KPMG. The document is comprehensive, contains financial data, investment project details, and is titled as a "专项报告" (special report) on the use of previously raised funds. This type of report is typically classified as a Capital/Financing Update (CAP) because it provides updates on the company's fundraising activities and the use of those funds, rather than being a full annual or interim financial report or an earnings release. It is not an announcement of a report publication, nor a certification or proxy material. Therefore, the best fitting category is Capital/Financing Update (CAP).
2024-11-20 Chinese
关于本次向特定对象发行A股股票不存在直接或通过利益相关方向参与认购的投资者提供财务资助或补偿事宜的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding a specific issuance of A shares to particular investors. It explicitly states that there is no financial assistance or compensation provided to investors involved in this issuance. The content focuses on the company's capital raising activity and related assurances, which aligns with updates on financing activities or capital structure changes. The document is short (493 characters) and is not a report or financial statement but an announcement about a capital issuance event. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2024-11-20 Chinese
关于最近五年未被证券监管部门和证券交易所采取监管措施或处罚的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Shenzhen Microchip Biotechnology Co., Ltd. stating that in the past five years, the company has not been subject to any regulatory measures or penalties by securities regulatory authorities or stock exchanges. It references a board meeting and self-inspection results but does not contain financial data, audit results, or detailed report content. The document is short (567 characters) and serves as a regulatory compliance announcement rather than a full report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and regulatory announcements.
2024-11-20 Chinese
第三届董事会独立董事专门会议2024年第一次会议决议
Board/Management Information Classification · 95% confidence The document is a resolution from the independent directors' special meeting of the board of Shenzhen Microcore Biotechnology Co., Ltd. It discusses approval of various proposals related to a specific issuance of A shares to targeted investors, including the issuance conditions, plans, feasibility reports, use of raised funds, and shareholder return plans. The document is a formal board meeting resolution with voting results and signatures, focusing on corporate governance and board decisions regarding capital raising activities. It is not a full financial report, earnings release, or regulatory filing but a board/management announcement about decisions made by the board. Therefore, the document fits best under Board/Management Information (MANG). The document length is 3560 characters, which is consistent with a meeting resolution rather than a full report.
2024-11-20 Chinese
关于2024年度向特定对象发行A股股票预案披露的提示性公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding a 2024 plan to issue A shares to specific investors. It mentions the board meeting approving the proposal and references related documents disclosed on the Shanghai Stock Exchange website. The text explicitly states this is a disclosure of the issuance plan and warns that the issuance is subject to shareholder approval and regulatory registration. There are no financial statements or detailed financial data included, and the document is short (575 characters). This fits the description of a Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes, specifically a share issuance plan to specific investors. It is not a full report, nor a mere announcement of a report publication, but an update on financing activity.
2024-11-20 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.